The stock of 89bio Inc (ETNB) has gone up by 21.15% for the week, with a 10.32% rise in the past month and a -8.13% drop in the past quarter. The volatility ratio for the week is 6.63%, and the volatility levels for the past 30 days are 11.11% for ETNB. The simple moving average for the past 20 days is 26.92% for ETNB’s stock, with a -2.81% simple moving average for the past 200 days.
Is It Worth Investing in 89bio Inc (NASDAQ: ETNB) Right Now?
Moreover, the 36-month beta value for ETNB is 1.48. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ETNB is 140.34M and currently, short sellers hold a 12.14% of that float. On May 01, 2025, ETNB’s average trading volume was 2.06M shares.
ETNB) stock’s latest price update
89bio Inc (NASDAQ: ETNB) has seen a rise in its stock price by 6.23 in relation to its previous close of 7.55. However, the company has experienced a 21.15% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-18 that Initiate Buy rating for 89bio, Inc. due to promising lead candidate pegozafermin targeting MASH and SHTG with encouraging Phase 2 data. Pegozafermin may have faster fibrosis improvement and better safety profile compared to competitors, potentially capturing significant market share in MASH and SHTG. Financially, 89bio has a solid cash position but may need to raise capital by mid to late 2026, posing dilution risk.
Analysts’ Opinion of ETNB
Many brokerage firms have already submitted their reports for ETNB stocks, with Goldman repeating the rating for ETNB by listing it as a “Neutral.” The predicted price for ETNB in the upcoming period, according to Goldman is $11 based on the research report published on March 14, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see ETNB reach a price target of $25. The rating they have provided for ETNB stocks is “Buy” according to the report published on March 13th, 2025.
ETNB Trading at 3.29% from the 50-Day Moving Average
After a stumble in the market that brought ETNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.26% of loss for the given period.
Volatility was left at 11.11%, however, over the last 30 days, the volatility rate increased by 6.63%, as shares surge +18.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.56% lower at present.
During the last 5 trading sessions, ETNB rose by +21.15%, which changed the moving average for the period of 200-days by -8.66% in comparison to the 20-day moving average, which settled at $6.32. In addition, 89bio Inc saw 2.56% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ETNB starting from Le-Nguyen Quoc, who sale 15,329 shares at the price of $5.95 back on Apr 15 ’25. After this action, Le-Nguyen Quoc now owns 328,323 shares of 89bio Inc, valued at $91,208 using the latest closing price.
QUOC LE-NGUYEN, the Officer of 89bio Inc, proposed sale 15,329 shares at $5.95 during a trade that took place back on Apr 15 ’25, which means that QUOC LE-NGUYEN is holding shares at $91,171 based on the most recent closing price.
Stock Fundamentals for ETNB
The total capital return value is set at -0.87. Equity return is now at value -78.34, with -68.30 for asset returns.
Based on 89bio Inc (ETNB), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -9.8. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -72.71.
Currently, EBITDA for the company is -384.66 million with net debt to EBITDA at 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.19.
Conclusion
To wrap up, the performance of 89bio Inc (ETNB) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
